Abstract:The development of effective cancer vaccines that can trigger strong and enduring memory T cell responses against specific tumor associated antigens (TAAs) is crucial for advancing immunotherapy. DNA-based cancer vaccines have shown promise in generating precise and long-lasting immune responses. In particular DNA vaccines are capable of inducing both humoral and cellular immune responses. In this study, we aimed to investigate the effectiveness of DNA vaccines targeting the mouse Tyrosine-related protein-2 (Trp2) and human New York esophageal squamous cell carcinoma 1 (NY-ESO-1) TAAs in mouse melanoma model. These DNA vaccines were formulated with a functionalized polymer designed to protect DNA from degradation and improve its bioavailability. DNA vaccines targeting both mouse Trp2 (pVACTR) and human NYESO-1 (pVACNY) were constructed. A mouse melanoma cell line (B16F10-NY) overexpressing human NYESO-1 was also generated and demonstrated to induce tumors in C57BL/6 mice. Female C57BL/6 mice received two doses of intramuscular (i.m.) injection of formulated pVACTR or pVACNY or a combination thereof, formulated with the synthetic functionalized polymer, with a 3-week interval. The DNA vaccination induced a potent T cell response, as evidenced by ELISPOT assays showing strong IFN-γ secreting T cells against NYESO-1 and Trp2. Flow cytometry analysis of spleenocytes showed strong IFN-γ and TNF-α secreting CD4 T cells against NYESO-1. We further evaluated the prophylactic and therapeutic efficacy of DNA vaccines targeting both Trp2 and NYESO-1 using a murine syngeneic model. Animals were challenged with a lethal dose of B16F10-NY two weeks after the second immunization exhibited a significant (p<0.0001) delay in tumor progression and a substantial increase in survival compared to the mock control group. In the therapeutic testing, animals challenged with B16F10-NY and subsequently vaccinated at 4, 11, and 25 days also demonstrated delayed tumor growth and prolonged survival. These findings indicate that formulated DNA vaccine delivered via i.m. triggers robust T cell responses and exhibit both prophylactic and therapeutic efficacy, leading to significantly prolonged survival and delayed tumor growth. A DNA-based vaccine independent of viral vector or device has potential to elicit potent anti-tumor responses with better safety and compliance. Citation Format: Kempaiah Rayavara, John Henderson, Meredyth Kinsella, Jessica Kim, Majed Matar, Subeena Sood, Olivia Signer, Chelsey Bellmon, Corinne Le Goff, Khursheed Anwer, Jean Boyer. Intramuscular delivery of tumor associated antigen DNA vaccines elicits strong cellular immune response, delays tumor growth and prolongs survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6748.

[Antitumor Effect of Gene Gun-Mediated DNA Vaccine Pwrg-Neu Immunization in C57BL/6 Mice].

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

HPV DNA vaccines expressing recombinant CRT/HPV6bE7 fusion protein inhibit tumor growth and angiogenic activity]

Anti-Tumor Efficacy Induced by Antibodized PDTRP Gene Immunization

HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

DC Targeting DNA Vaccines Induce Protective and Therapeutic Antitumor Immunity in Mice.

A Dna Vaccine Targeting P42.3 Induces Protective Antitumor Immunity Via Eliciting Cytotoxic Cd8(+)T Lymphocytes In A Murine Melanoma Model

[Anti-Tumor Effect Through Human Endostatin Gene Transfer in Mice Bearing B16 Melanoma].

Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

Therapeutic Effect of Combined Treatment with CD Suicide Gene and GM-CSF Gene on Murine Melanoma and Its Immunological Mechanism

The potent antitumor effects of combined p16 gene and GM-CSF gene therapy through efficient induction of antitumor immunity

Inhibition of melanoma by survivin-specific lymphocytes combined with CCL17 and granulocyte-macrophage colony-stimulating factor in a mouse syngeneic model

The Expression and Protective Efficacy of DNA Vaccine Encoding Antibodized Hgp100

Systemic genetic transfer of p21 WAF − 1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex

The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma

Abstract 6748: Intramuscular delivery of tumor associated antigen DNA vaccines elicits strong cellular immune response, delays tumor growth and prolongs survival

Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

Antitumor effect of granulocyte-macrophage colony-stimulating factor (GM-CSF)-gene encoded vaccinia melanoma oncolysate and its immunological mechanisms

Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model